<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->

### Database Entries (Nov 20)
Andreano E, Nicastri E, et int., and Rappuoli R. [‚ÄúExtremely potent human monoclonal antibodies from convalescent Covid-19 patients.‚Äù](/search/?article=Andreano20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.07.328302](https://doi.org/10.1101/2020.10.07.328302).
### Database Entries (Nov 20)
Bracken CJ, Lim SA, et int., and Wells JA. [‚ÄúBi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.‚Äù](/search/?article=Bracken20) _Nature Chemical Biology_, 2020. [doi.org/10.1038/s41589-020-00679-1](https://doi.org/10.1038/s41589-020-00679-1). \[[PubMed33082574](https://www.ncbi.nlm.nih.gov/pubmed/33082574/)\]
### Database Entries (Nov 20)
Tortorici MA, Beltramello M, et int., and Veesler D. [‚ÄúUltrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.‚Äù](/search/?article=Tortorici20) _Science_, 2020. [doi.org/10.1126/science.abe3354](https://doi.org/10.1126/science.abe3354). \[[PubMed32972994](https://www.ncbi.nlm.nih.gov/pubmed/32972994/)\]

### [Clinical Trials (Nov 19)](/page/updates/#clinical.trials)
[10 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-19)

### Database Entries (Nov 19)
Barnes CO, Jette CA, et int., and Bjorkman PJ. [‚ÄúSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.‚Äù](/search/?article=Barnes20b) _Nature_, 2020. [doi.org/10.1038/s41586-020-2852-1](https://doi.org/10.1038/s41586-020-2852-1). \[[PubMed33045718](https://www.ncbi.nlm.nih.gov/pubmed/33045718/)\]
### Database Entries (Nov 19)
Van Damme E, De Meyer S, et int., and Van Loock M. [‚ÄúIn Vitro Activity of Itraconazole Against SARS-CoV-2.‚Äù](/search/?article=Damme20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.13.381194](https://doi.org/10.1101/2020.11.13.381194).
### Database Entries (Nov 19)
Gendrot M, Andreani J, et int., and Pradines B. [‚ÄúIn Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.‚Äù](/search/?article=Gendrot20) _Molecules_, 2020. [doi.org/10.3390/molecules25215064](https://doi.org/10.3390/molecules25215064). \[[PubMed33142770](https://www.ncbi.nlm.nih.gov/pubmed/33142770/)\] \[[PMC7663271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663271/)\]
### Database Entries (Nov 19)
Wang S, Peng Y, et int., and Liu D. [‚ÄúCharacterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.‚Äù](/search/?article=Wang20l) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-19568-1](https://doi.org/10.1038/s41467-020-19568-1). \[[PubMed33188207](https://www.ncbi.nlm.nih.gov/pubmed/33188207/)\] \[[PMC7666115](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666115/)\]

### [Published preprints - week of November 16](/page/updates/#published.preprints)
[Hurlburt NK](/search/?article=Hurlburt20) (_Nature Communications_); [Sacco MD](/search/?article=Sacco20) (_Science Advances_); [Zhang Q](/search/?article=Zhang20e) (_Cell Discovery_)
### Database Entries (Nov 17)
Monk PD, Marsden RJ, et int., and Rodrigues PM. [‚ÄúSafety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.‚Äù](/search/?article=Monk20) _The Lancet Respiratory Medicine_, 2020. [doi.org/10.1016/s2213-2600(20)30511-7](https://doi.org/10.1016/s2213-2600(20)30511-7). \[[PubMed33189161](https://www.ncbi.nlm.nih.gov/pubmed/33189161/)\]
### Database Entries (Nov 17)
Shi Y, Shuai L, et int., and Peng G. [‚ÄúThe Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract.‚Äù](/search/?article=Shi20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.12.380931](https://doi.org/10.1101/2020.11.12.380931).


### Database Entries (Nov 13)
Cornelissen L, Hoefsmit E, et int., and Blank CU. [‚ÄúNafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model.‚Äù](/search/?article=Cornelissen20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.09.372375](https://doi.org/10.1101/2020.11.09.372375).
### Database Entries (Nov 13)
Feld JJ, Kandel C, et int., and Hansen B. [‚ÄúPeginterferon-lambda for the treatment of COVID-19 in outpatients.‚Äù](/search/?article=Feld20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.09.20228098](https://doi.org/10.1101/2020.11.09.20228098).
### Database Entries (Nov 13)
Lee S, Kim C, et int., and Choi YK. [‚ÄúA Novel Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV-2.‚Äù](/search/?article=Lee20b) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-59639/v1](https://doi.org/10.21203/rs.3.rs-59639/v1).

### [Clinical Trials (Nov 12)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-12)

### [Press Release (Nov 10)](/page/updates/#press.release)
[Bamlanivimab EUA Letter of Authorization](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202011101.pdf)

### [Press Release (Nov 10)](/page/updates/#press.release)
[Bamlanivimab EUA Letter of Authorization FAQ](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202011102.pdf)

### [Press Release (Nov 9)](/page/updates/#press.release)
[Pfizer and biontech announce vaccine candidate against covid-19 achieved sucess in first interim analysis from phase 3 study](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Pfizer20201109.pdf)

### [Published preprints - week of November 9](/page/updates/#published.preprints)
[Beddingfield BJ](/search/?article=Beddingfield20) (_JACC Basic Transl Sci_); [Chen CZ](/search/?article=Chen20f) (_ACS Pharmacol. Transl. Sci._); [Ghahremanpour MM](/search/?article=Ghahremanpour20) (_ACS Med. Chem. Lett._); [Lou Y](/search/?article=Lou20) (_EJPS_); [Tandon R](/search/?article=Tandon20) (_Journal of Virology_)
### Database Entries (Nov 09)
Westberg M, Su Y, et int., and Lin MZ. [‚ÄúRational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases.‚Äù](/search/?article=Westberg20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.15.275891](https://doi.org/10.1101/2020.09.15.275891).
### Database Entries (Nov 07)
Chi X, Liu X, et int., and Yang W. [‚ÄúHumanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.‚Äù](/search/?article=Chi20b) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18387-8](https://doi.org/10.1038/s41467-020-18387-8). \[[PubMed32913273](https://www.ncbi.nlm.nih.gov/pubmed/32913273/)\] \[[PMC7483421](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483421/)\]
### Database Entries (Nov 07)
de Vries RD, Schmitz KS, et int., and Porotto M. [‚ÄúIntranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets.‚Äù](/search/?article=deVries20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.04.361154](https://doi.org/10.1101/2020.11.04.361154).

### [Published preprints - week of November 2](/page/updates/#published.preprints)
[Cust√≥dio TF](/search/?article=Custodio20) (_Ncomms_); [Schoof M](/search/?article=Schoof20) (_Science_); [Li W](/search/?article=Li20b) (_PNAS_); [Kreye J](/search/?article=Kreye20) (_Cell_); [Matsuyama S](/search/?article=Matsuyama20) (_JVI_)
### [Clinical Trials (Nov 05)](/page/updates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-05)

### Database Entries (Nov 05)
Bojkova D, Bechtel M, et int., and Cinatl J. [‚ÄúAprotinin Inhibits SARS-CoV-2 Replication.‚Äù](/search/?article=Bojkova20c) _Cells_, 2020. [doi.org/10.3390/cells9112377](https://doi.org/10.3390/cells9112377). \[[PubMed33143316](https://www.ncbi.nlm.nih.gov/pubmed/33143316/)\]
### Database Entries (Nov 05)
Li Y, Cao L, et int., and Zhang X. [‚ÄúRemdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models.‚Äù](/search/?article=Li20g) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.353300](https://doi.org/10.1101/2020.10.26.353300).
### Database Entries (Nov 04)
Cai Y, Xu W, et int., and Jiang S. [‚ÄúGriffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit.‚Äù](/search/?article=Cai20b) _Virologica Sinica_, 2020. [doi.org/10.1007/s12250-020-00305-3](https://doi.org/10.1007/s12250-020-00305-3). \[[PubMed33052520](https://www.ncbi.nlm.nih.gov/pubmed/33052520/)\] \[[PMC7554295](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554295/)\]
### Database Entries (Nov 04)
Weisblum Y, Schmidt F, et int., and Bieniasz PD. [‚ÄúEscape from neutralizing antibodies by SARS-CoV-2 spike protein variants.‚Äù](/search/?article=Weisblum20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.21.214759](https://doi.org/10.1101/2020.07.21.214759). \[[PubMed32743579](https://www.ncbi.nlm.nih.gov/pubmed/32743579/)\] \[[PMC7386497](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386497/)\]
### Database Entries (Nov 04)
Yuan S, Yin X, et int., and Yuen K. [‚ÄúClofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters.‚Äù](/search/?article=Yuan20e) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-86169/v1](https://doi.org/10.21203/rs.3.rs-86169/v1). \[[PubMed33052331](https://www.ncbi.nlm.nih.gov/pubmed/33052331/)\] \[[PMC7553155](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/)\]
### Database Entries (Nov 03)
Bakovic A, Risner K, et int., and Narayanan A. [‚ÄúBrilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2.‚Äù](/search/?article=Bakovic20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.29.352450](https://doi.org/10.1101/2020.10.29.352450).
### Database Entries (Nov 03)
Chan CE, Seah SG, et int., and Hanson BJ. [‚ÄúThe Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.‚Äù](/search/?article=Chan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.355107](https://doi.org/10.1101/2020.10.26.355107).
### Database Entries (Nov 03)
Fu Y, Maruyama J, et int., and Allen RD. [‚ÄúProtective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model.‚Äù](/search/?article=Fu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.28.359836](https://doi.org/10.1101/2020.10.28.359836).
### Database Entries (Nov 03)
Halfon P, Bestion E, et int., and Schinazi RF. [‚ÄúGNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.‚Äù](/search/?article=Halfon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.327635](https://doi.org/10.1101/2020.10.06.327635). \[[PubMed33052342](https://www.ncbi.nlm.nih.gov/pubmed/33052342/)\] \[[PMC7553169](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553169/)\]
### Database Entries (Nov 03)
Hashim HA, Maulood MF, et int., and Abdulamir AS. [‚ÄúControlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.‚Äù](/search/?article=Hashim20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.26.20219345](https://doi.org/10.1101/2020.10.26.20219345).
### Database Entries (Nov 03)
Li T, Sun L, et int., and Shen X. [‚ÄúBromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‚Äê19: An Open‚ÄêLabel Randomized Controlled Pilot Study.‚Äù](/search/?article=Li20f) _Clinical and Translational Science_, 2020. [doi.org/10.1111/cts.12881](https://doi.org/10.1111/cts.12881). \[[PubMed32881359](https://www.ncbi.nlm.nih.gov/pubmed/32881359/)\]
### Database Entries (Nov 03)
Mellott D, Tseng C, et int., and McKerrow JH. [‚ÄúA cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.‚Äù](/search/?article=Mellott20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.23.347534](https://doi.org/10.1101/2020.10.23.347534).
### Database Entries (Nov 03)
Rosenfeld R, Noy-Porat T, et int., and Mazor O. [‚ÄúPost-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.‚Äù](/search/?article=Rosenfeld20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.354811](https://doi.org/10.1101/2020.10.26.354811).
### Database Entries (Nov 03)
Zandi K, Amblard F, et int., and Schinazi RF. [‚ÄúRepurposing Nucleoside Analogs for Human Coronaviruses.‚Äù](/search/?article=Zandi20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01652-20](https://doi.org/10.1128/aac.01652-20). \[[PubMed33122172](https://www.ncbi.nlm.nih.gov/pubmed/33122172/)\]

### Database Entries (Nov 02)
Cao X, Maruyama J, et int., and Allen RD. [‚ÄúDiscovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach.‚Äù](/search/?article=Cao20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.27.316174](https://doi.org/10.1101/2020.09.27.316174).

### [Press Release (Oct 30)](/page/updates/#press.release)
[Regn-cov2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201030.pdf)

### [Clinical Trials (Oct 29)](/page/updates/#clinical.trials)
[11 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-29)

### Database Entries (Oct 29)
Chen P, Nirula A, et int., and Skovronsky DM. [‚ÄúSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.‚Äù](/search/?article=Chen20l) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2029849](https://doi.org/10.1056/nejmoa2029849). \[[PubMed33113295](https://www.ncbi.nlm.nih.gov/pubmed/33113295/)\]
### [Press Release (Oct 28)](/page/updates/#press.release)
[Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN- COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201028.pdf)

### [Press Release (Oct 26)](/page/updates/#press.release)

[Lilly Statement Regarding NIH‚Äôs ACTIV-3 Clinical Trial](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20201027.pdf)

### Database Entries (Oct 26)
Pan H, Peto R, et int., and Swaminathan S. [‚ÄúRepurposed antiviral drugs for COVID-19 ‚Äìinterim WHO SOLIDARITY trial results.‚Äù](/search/?article=Pan20b) _medRxiv_, 2020. [doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817).
### Database Entries (Oct 26)
Rocco PRM, Silva PL, et int., and Lapa e Silva JR. [‚ÄúEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial.‚Äù](/search/?article=Rocco20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.21.20217208](https://doi.org/10.1101/2020.10.21.20217208).

### [Clinical Trials (Oct 22)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-22)
### Database Entries (Oct 22)
Rosenke K, Leventhal S, et int., and Stein DA. [‚ÄúInhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomers.‚Äù](/search/?article=Rosenke20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.29.319731](https://doi.org/10.1101/2020.09.29.319731). \[[PubMed33024974](https://www.ncbi.nlm.nih.gov/pubmed/33024974/)\] \[[PMC7536879](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536879/)\]
### Database Entries (Oct 22)
Yin W, Luan X, et int., and Xu HE. [‚ÄúStructural basis for repurposing a 100-years-old drug suramin for treating COVID-19.‚Äù](/search/?article=yin20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.328336](https://doi.org/10.1101/2020.10.06.328336).


